[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07731139":3,"trial-entities:NCT07731139":81,"trial-summary:NCT07731139":84},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":21,"phases":22,"enrollment_info":24,"interventions":27,"primary_outcomes":37,"secondary_outcomes":41,"sex":47,"minimum_age":48,"maximum_age":49,"healthy_volunteers":14,"eligibility_criteria":50,"std_ages":54,"locations":57,"central_contacts":67,"overall_officials":73,"references":76,"see_also_links":77},"NCT07731139","C6601003","A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity","A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO INVESTIGATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ASCENDING ORAL DOSES OF PF-08642534 IN ADULTS WITH OBESITY","NOT_YET_RECRUITING","2027-04-21","2026-07","2026-07-28","Pfizer","INDUSTRY",false,"This study will look at a study drug called PF-08642534 in people with obesity (have too much body weight) to see: if participants can take different amounts (doses) of the study drug in a safe way and how adults with obesity tolerate it, and how the body handles the study drug (for example, how the study drug is absorbed and removed from the body).\n\nPeople who want to join the study will first go through a screening period of up to 4 weeks. Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study.",null,[18],"Obesity",[],"INTERVENTIONAL","BASIC_SCIENCE",[23],"PHASE1",{"count":25,"type":26},120,"ESTIMATED",[28,33],{"type":29,"name":30,"description":31,"armGroupLabels":32},"DRUG","PF-08642534","Participants will receive PF-08642534 QD (once a day)",[30],{"type":29,"name":34,"description":35,"armGroupLabels":36},"Placebo","Participants will receive matching placebo QD (once a day)",[34],[38],{"measure":39,"timeFrame":40},"Incidence of treatment emergent adverse events (TEAE)","Baseline up to 8 weeks after last dose",[42,45],{"measure":43,"timeFrame":44},"Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-08642534","0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24 hours post-dose",{"measure":46,"timeFrame":44},"Maximum Observed Plasma Concentration (Cmax) of PF-08642534","ALL","18 Years","70 Years",{"inclusion":51,"exclusion":52,"raw_text":53},[],[],"Inclusion:\n\n* Body mass index (BMI) ≥30.0 and ≤40.0 kg\u002Fm², and with stable body weight prior to screening.\n* Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension)\n\nExclusion:\n\n\\- Individuals with diabetes, significant cardiovascular, hepatic, renal, gastrointestinal, or psychiatric disorders, or conditions that may affect drug absorption or metabolism, are not eligible to participate.",[55,56],"ADULT","OLDER_ADULT",[58],{"facility":59,"city":60,"state":61,"zip":62,"country":63,"geoPoint":64},"Orange County Research Center","Lake Forest","California","92630","United States",{"lat":65,"lon":66},33.64697,-117.68922,[68],{"name":69,"role":70,"phone":71,"email":72},"Pfizer CT.gov Call Center","CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[74],{"name":69,"affiliation":12,"role":75},"STUDY_DIRECTOR",[],[78],{"label":79,"url":80},"To obtain contact information for a study center near you, click here.","https:\u002F\u002Fpmiform.com\u002Fclinical-trial-info-request?StudyID=C6601003",{"nct_id":4,"conditions":82,"biomarkers":83},[18],[],{"nct_id":4,"found":85,"summary":86,"prompt_version":96},true,{"design":87,"status":88,"heading":89,"summary":90,"follow_up":91,"word_count":92,"commitments":93,"compensation":94,"drugs_mentioned":95},"This is an interventional study planning to enroll 120 participants. Some participants will receive PF-08642534 once a day, while others will receive a placebo (an inactive substance) once a day.","completed","A Study of PF-08642534 for Obesity","This study is looking at a medicine called PF-08642534 for people who have obesity (too much body weight). Researchers want to find out if different amounts of PF-08642534 are safe and how well people tolerate them. They also want to understand how the body uses and removes the medicine. You might be able to join if you are between 18 and 70 years old, have a Body Mass Index (BMI) between 30.0 and 40.0 kg\u002Fm², and are generally healthy. People with certain medical conditions, like diabetes or significant heart problems, cannot participate. The main goal is to track any side effects you might experience up to 8 weeks after your last dose.","You will be monitored for side effects up to 8 weeks after your last dose of the study medicine.",112,"You will go through a screening period of up to 4 weeks to see if you meet the study requirements.","Not stated in the trial record.",[30],"v2"]